Develops vaccines for infectious diseases, including hepatitis B, cytomegalovirus, and coronaviruses.
VBI Vaccines Inc., a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, is dedicated to developing and commercializing vaccines for infectious diseases and immuno-oncology. Known for its innovative Sci-B-Vac, a highly effective prophylactic hepatitis B (HBV) vaccine, VBI Vaccines Inc. continues to expand its portfolio with advanced immunotherapeutic candidates. Notably, VBI-2601 (BRII-179) is currently in development for treating chronic HBV infection, leveraging the company's enveloped virus-like particle (eVLP) platform technology.
The eVLP platform enables VBI Vaccines Inc. to mimic virus presentation, effectively stimulating the human immune response. Leading eVLP program candidates include VBI-1901, an immunotherapeutic vaccine for glioblastoma undergoing Phase I/IIa clinical trials, and VBI-1501, a prophylactic cytomegalovirus vaccine that has completed Phase I testing. The company is also advancing coronavirus vaccine candidates such as VBI-2902 and VBI-2901, underscoring its commitment to addressing emerging infectious threats.
Beyond its proprietary pipeline, VBI Vaccines Inc. collaborates with global partners like Brii Biosciences Limited, GlaxoSmithKline Biologicals S.A., and the National Research Council of Canada. These collaborations aim to develop and license vaccine platforms and products, including a pan-coronavirus vaccine targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. Additionally, the company collaborates with the Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against COVID-19 variants, further solidifying its role in global health initiatives.